ALDESCREEN®
Diagnostic for patient stratification
Commercial/DevelopmentDeveloped
Key Facts
Indication
Diagnostic for patient stratification
Phase
Commercial/Development
Status
Developed
Company
About Advanced Biodesign
Advanced BioDesign is a French biotech founded in 2010 with a mission to treat chemotherapy-resistant cancers by targeting the ALDH1 enzyme family, a key driver of tumor drug resistance and immunomodulation. The company has progressed its lead small-molecule inhibitor, ABD-3001, into clinical trials for AML and has a promising pre-clinical pipeline for solid tumors. Its integrated strategy combines therapeutic inhibitors with a companion diagnostic, ALDESCREEN®, aiming to personalize treatment and improve outcomes for patients with resistant cancers.
View full company profile